


Personalizing adjuvant therapy decisions in ER+ & HER2- breast cancer



Patient selection considerations are based on data from the suite of Oncotype DX studies, including: NSABP B-14, NSABP B-20, TransATAC, and SWOG 8814.^{1-3,6}

^{*}Al=aromatase inhibitor.

^{†&}gt;0.5 cm

[‡]Consider patients from a subset of stage IIIa as indicated, not all stage III patients.

Oncotype DX® online portal

 Access your patients' test results and order Oncotype DX online at https://online.genomichealth.com

Oncotype DX insurance for patients

- More than 95% of US privately insured lives in node negative breast cancer covered⁷
- Payment by selected payers for patients with micrometastatic disease and node-positive disease
- Genomic Access Program (GAP) and Financial Assistance Program (FAP) broadens access based on patient's financial eligibility

Oncotype DX Customer Service/Reimbursement

You can contact Genomic Health at 1-866-ONCOTYPE (1-866-662-6897) or by e-mail at customerservice@genomichealth.com.

www.oncotypeDX.com

References: 1. Paik S, et al. A multigene assay to predict recurrence of tarnoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826. 2. Paik S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Olin Oncol. 2006;24(23):3726-3734. 3. Dowsett M, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopause) patients with breast cancer treated with anastrozole or tarnoxifer: a TransATAC study. J Olin Oncol. 2010;28(11):1829-34. 4. Harris L, et al. ASCO 2007 update of recommendations for the use of tumor markers in breast cancer. J Olin Oncol. 2007;25(33):5287-5312. 5. NCCN Clinical Practice Guidelines in Oncology^{1M}. Breast cancer. V1.2011. Available at: http://www.nccn.org, accessed December 6, 2010. 6. Albain KS, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65. 7. Data on file at Genomic Health Inc.





Genomic Health and Oncotype DX are registered trademarks of Genomic Health, Inc.
American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer
Network, NCON, and NCON Guidelines are trademarks of NCON. ASCO and NCON do not endorse any product or therapy.

© 2011 Genomic Health, Inc. All rights reserved.

GH10042_0911